港股异动 | 石药集团(01093)反弹近4% 大摩指其盈警对股价影响不大看好今年新药销售业务

智通财经2025-02-27

智通财经APP获悉，石药集团(01093)反弹近4%，截至发稿，涨3.94%，报5.01港元，成交额6.86亿港元。消息面上，石药集团此前发盈警，预计集团截至2024年12月31日止年度的公司拥有人应占溢利将同比减少约26%。大摩认为，由于传统药品价格在集中采购(VBPs)渠道内下跌，很大程度上投资者已预料其利润下跌，因此认为这次盈警对其股价影响不大。从正面来看，管理层早前表示，旗下药物恩必普(...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2514823017?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-27 15:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514823017","market":"hk","top_or_hot":-1,"title":"港股异动 | 石药集团(01093)反弹近4% 大摩指其盈警对股价影响不大 看好今年新药销售业务","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，石药集团(01093)反弹近4%，截至发稿，涨3.94%，报5.01港元，成交额6.86亿港元。消息面上，石药集团此前发盈警，预计集团截至2024年12月31日止年度的公司拥有人应占溢利将同比减少约26%。大摩认为，由于传统药品价格在集中采购(VBPs)渠道内下跌，很大程度上投资者已预料其利润下跌，因此认为这次盈警对其股价影响不大。从正面来看，管理层早前表示，旗下药物恩必普(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1255179.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 石药集团(01093)反弹近4% 大摩指其盈警对股价影响不大 看好今年新药销售业务</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 石药集团(01093)反弹近4% 大摩指其盈警对股价影响不大 看好今年新药销售业务\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-27 15:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1255179.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，石药集团(01093)反弹近4%，截至发稿，涨3.94%，报5.01港元，成交额6.86亿港元。消息面上，石药集团此前发盈警，预计集团截至2024年12月31日止年度的公司拥有人应占溢利将同比减少约26%。大摩认为，由于传统药品价格在集中采购(VBPs)渠道内下跌，很大程度上投资者已预料其利润下跌，因此认为这次盈警对其股价影响不大。从正面来看，管理层早前表示，旗下药物恩必普(...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1255179.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1226287529.USD","symbol_name":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1255179.html","article_id":"2514823017","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514823017","pubTimestamp":1740641345,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，石药集团反弹近4%，截至发稿，涨3.94%，报5.01港元，成交额6.86亿港元。消息面上，石药集团此前发盈警，预计集团截至2024年12月31日止年度的公司拥有人应占溢利将同比减少约26%。大摩认为，由于传统药品价格在集中采购渠道内下跌，很大程度上投资者已预料其利润下跌，因此认为这次盈警对其股价影响不大。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","01093":"石药集团","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4581":"高盛持仓","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","BK1515":"抗疫概念","LU0140636845.USD":"施罗德大中华区股票A Acc","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","BK4585":"ETF&股票定投概念","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK4516":"特朗普概念","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","BK4504":"桥水持仓","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC"},"translate_title":"Changes in Hong Kong stocks CSPC Pharmaceutical Group (01093) rebounded nearly 4% Morgan Stanley said its profit warning had little impact on stock prices and was optimistic about this year's new drug sales business","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"智通财经APP获悉，石药集团(01093)反弹近4%，截至发稿，涨3.94%，报5.01港元，成交额6.86亿港元。消息面上，石药集团此前发盈警，预计集团截至2024年12月31日止年度的公司拥有人应占溢利将同比减少约26%。大摩认为，由于传统药品价格在集中采购(VBPs)渠道内下跌，很大程度上投资者已预料其利润下跌，因此认为这次盈警对其股价影响不大。从正面来看，管理层早前表示，旗下药物恩必普(NBP)第四季销售呈按季良好复苏，而新药销售业务去年贡献20亿元人民币，料今年将会倍增。野村则表示，对石药2024财年的营收及盈利预测，较市场普遍预期低0.9%及0.8%；至于对2025财年的预测则高出0.1%及0.9%。该行指出，理解石药在成熟业务方面面临压力，但认为公司最近对早期资产的对外授权部分，缓解了相关压力。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2514823017","isCrawlerRequest":true}

港股异动 | 石药集团(01093)反弹近4% 大摩指其盈警对股价影响不大 看好今年新药销售业务

精彩评论

港股异动 | 石药集团(01093)反弹近4% 大摩指其盈警对股价影响不大看好今年新药销售业务